• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?托伐普坦治疗常染色体显性多囊肾病的证据负担：REPRISE研究给出答案了吗？
Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1107-1109. doi: 10.2215/CJN.00190118. Epub 2018 Apr 13.
2
A Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.托伐普坦治疗常染色体显性遗传多囊肾病关键性试验中他汀类药物的使用分析。
Clin J Am Soc Nephrol. 2020 May 7;15(5):643-650. doi: 10.2215/CJN.08170719. Epub 2020 Apr 2.
3
An update on tolvaptan for autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传性多囊肾病的最新进展
Drugs Today (Barc). 2018 Sep;54(9):519-533. doi: 10.1358/dot.2018.54.9.2776624.
4
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.托伐普坦治疗对常染色体显性多囊肾病肾功能下降的长期益处建模：使用常染色体显性多囊肾病结局模型的探索性分析
BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5.
5
Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.常染色体显性多囊肾病（ADPKD）试验参与者中托伐普坦相关肝损伤的临床模式：关键临床试验分析
Am J Kidney Dis. 2023 Mar;81(3):281-293.e1. doi: 10.1053/j.ajkd.2022.08.012. Epub 2022 Sep 30.
6
A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.一种疾病进展模型，用于估计托伐普坦对快速进展性常染色体显性多囊肾病患者终末期肾病时间的获益。
BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8.
7
[ADPKD treatment: Tolvaptan and Octreotide].[常染色体显性多囊肾病的治疗：托伐普坦和奥曲肽]
G Ital Nefrol. 2019 Dec 9;36(6):2019-vol6.
8
[Tolvaptan, a vasopressin V receptor antagonist, is the world's first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)].托伐普坦，一种血管加压素V受体拮抗剂，是世界上首个获批用于治疗常染色体显性遗传性多囊肾病（ADPKD）的药物。
Nihon Yakurigaku Zasshi. 2022;157(4):254-260. doi: 10.1254/fpj.22006.
9
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?探讨血管加压素拮抗剂在多囊肾病中的作用：从成人到儿童？
Pediatr Nephrol. 2018 Mar;33(3):395-408. doi: 10.1007/s00467-017-3672-x. Epub 2017 Apr 28.
10
Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice.托伐普坦用于常染色体显性多囊肾病：药代动力学及对临床实践的意义
Nephrol Nurs J. 2020 Mar-Apr;47(2):145-150.

引用本文的文献

1
Therapeutic Potential of Ketogenic Interventions for Autosomal-Dominant Polycystic Kidney Disease: A Systematic Review.生酮干预对常染色体显性多囊肾病的治疗潜力：一项系统评价
Nutrients. 2024 Dec 31;17(1):145. doi: 10.3390/nu17010145.
2
Targeting the ADPKD methylome using nanoparticle-mediated combination therapy.使用纳米颗粒介导的联合疗法靶向常染色体显性多囊肾病甲基化组。
APL Bioeng. 2023 Jun 9;7(2):026111. doi: 10.1063/5.0151408. eCollection 2023 Jun.
3
1-Indanone retards cyst development in ADPKD mouse model by stabilizing tubulin and down-regulating anterograde transport of cilia.1-茚满酮通过稳定微管蛋白和下调纤毛的正向转运来延缓 ADPKD 小鼠模型中的囊肿发育。
Acta Pharmacol Sin. 2023 Feb;44(2):406-420. doi: 10.1038/s41401-022-00937-z. Epub 2022 Jul 29.
4
Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment.天然衍生化合物及其在潜在常染色体显性遗传性多囊肾病（ADPKD）治疗中的作用机制。
Clin Exp Nephrol. 2021 Nov;25(11):1163-1172. doi: 10.1007/s10157-021-02111-x. Epub 2021 Jul 12.
5
Per-Treatment Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD.托伐普坦治疗常染色体显性多囊肾病临床试验结果的治疗前分析
Kidney Int Rep. 2021 Feb 2;6(4):1032-1040. doi: 10.1016/j.ekir.2021.01.014. eCollection 2021 Apr.
6
Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review.常染色体显性多囊肾病的研究进展：临床综述
Kidney Med. 2020 Feb 22;2(2):196-208. doi: 10.1016/j.xkme.2019.11.009. eCollection 2020 Mar-Apr.
7
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.托伐普坦：常染色体显性遗传多囊肾病治疗药物的研究进展。
Drugs. 2019 Feb;79(3):303-313. doi: 10.1007/s40265-019-1056-1.

本文引用的文献

1
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.常染色体显性多囊肾病临床试验中的预后富集设计：TEMPO 3:4临床试验
Kidney Int Rep. 2016 Aug 6;1(4):213-220. doi: 10.1016/j.ekir.2016.08.001. eCollection 2016 Nov.
2
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗晚期常染色体显性遗传性多囊肾病。
N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.
3
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.能否进一步丰富常染色体显性遗传多囊肾病快速进展患者的临床试验？PROPKD 评分在 TEMPO 试验中的应用。
Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188.
4
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.多中心、开放标签、扩展试验，旨在评估托伐普坦早期治疗与延迟治疗对常染色体显性多囊肾病的长期疗效和安全性：TEMPO 4:4试验
Nephrol Dial Transplant. 2017 Jul 1;32(7):1262. doi: 10.1093/ndt/gfx079.
5
The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.PROPKD评分：一种预测常染色体显性多囊肾病肾脏存活情况的新算法。
J Am Soc Nephrol. 2016 Mar;27(3):942-51. doi: 10.1681/ASN.2015010016. Epub 2015 Jul 6.
6
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.常染色体显性遗传多囊肾病的影像学分类：一种用于选择临床试验患者的简单模型。
J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5.
7
Autosomal dominant polycystic kidney disease.常染色体显性多囊肾病
Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1.
8
Volume progression in polycystic kidney disease.多囊肾病中的体积进展
N Engl J Med. 2006 May 18;354(20):2122-30. doi: 10.1056/NEJMoa054341.
9
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.氯沙坦对2型糖尿病肾病患者肾脏和心血管结局的影响。
N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161.

Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?

作者信息

Mustafa Reem A, Yu Alan S L

机构信息

Division of Nephrology and Hypertension, Department of Internal Medicine and The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas.

出版信息

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1107-1109. doi: 10.2215/CJN.00190118. Epub 2018 Apr 13.

DOI:10.2215/CJN.00190118
PMID:29653956
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6032588/
Abstract
摘要